-
公开(公告)号：US10472376B2
公开(公告)日：2019-11-12
申请号：US14902388
申请日：2014-07-02
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Satoshi Yamamoto , Junya Shirai , Mitsunori Kono , Yoshihide Tomata , Ayumu Sato , Atsuko Ochida , Yoshiyuki Fukase , Shoji Fukumoto , Tsuneo Oda , Hidekazu Tokuhara , Naoki Ishii , Yusuke Sasaki
IPC: C07F7/08 , C07D309/06 , C07D405/12 , C07D239/36 , C07D413/12 , C07D205/04 , C07C237/22 , C07D207/12 , C07D271/10 , C07F7/10 , C07F7/30 , C07K5/065 , C07D309/08 , C07D231/12 , C07D231/56 , C07D333/38 , C07D233/72 , C07D403/06 , C07D237/14 , C07D239/54 , C07K5/087
Abstract: The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.
-
公开(公告)号：US10000488B2
公开(公告)日：2018-06-19
申请号：US15510225
申请日：2015-09-10
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Satoshi Yamamoto , Junya Shirai , Tsuneo Oda , Takashi Imada , Mitsunori Kono , Ayumu Sato , Yoshihide Tomata , Atsuko Ochida , Naoki Ishii , Yusuke Sasaki , Yoshiyuki Fukase , Tomoya Yukawa , Shoji Fukumoto
IPC: C07D471/04 , C07D401/14 , C07D413/12 , C07D405/12 , C07D405/14 , C07D413/14 , C07D239/96 , C07D409/14 , C07D403/12 , C07D401/12 , C07D417/14 , C07D417/12
CPC classification number: C07D471/04 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K31/551 , A61P1/00 , A61P11/00 , C07D239/96 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
Abstract: The problem of the present invention is to provide a compound having a superior RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.
-
公开(公告)号：US09630924B2
公开(公告)日：2017-04-25
申请号：US15055108
申请日：2016-02-26
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Satoshi Yamamoto , Junya Shirai , Tsuneo Oda , Mitsunori Kono , Atsuko Ochida , Takashi Imada , Hidekazu Tokuhara , Yoshihide Tomata , Naoki Ishii , Michiko Tawada , Yoshiyuki Fukase , Tomoya Yukawa , Shoji Fukumoto
IPC: C07D471/04 , C07D215/00 , C07D217/26 , C07F7/08 , C07D491/048 , C07D491/056 , A61K31/4375 , A61K31/472 , A61K31/4741 , C07D217/14 , C07D491/14
CPC classification number: C07D217/26 , A61K31/4375 , A61K31/472 , A61K31/4741 , C07D217/14 , C07D471/04 , C07D491/048 , C07D491/056 , C07D491/14 , C07F7/0812
Abstract: The present invention provides a heterocyclic compound having a RORγt inhibitory action.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification. or a salt thereof.
-
公开(公告)号：US09663514B2
公开(公告)日：2017-05-30
申请号：US14706876
申请日：2015-05-07
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Mitsunori Kono , Zhe Nie
IPC: C07D471/04 , C07D519/00 , A61K31/4365 , A61K31/437 , A61K31/4985 , A61K31/519 , A61K31/5383 , C07D487/04 , C07D495/04 , C07D498/04 , A61K31/5365
CPC classification number: C07D471/04 , A61K31/4365 , A61K31/437 , A61K31/4985 , A61K31/519 , A61K31/5365 , A61K31/5383 , C07D487/04 , C07D495/04 , C07D498/04 , C07D519/00
Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, p, R1, R2, R3a, R4, and R5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
-
公开(公告)号：US20210277030A1
公开(公告)日：2021-09-09
申请号：US17316185
申请日：2021-05-10
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Satoshi Yamamoto , Junya Shirai , Mitsunori Kono , Yoshihide Tomata , Ayumu Sato , Atsuko Ochida , Yoshiyuki Fukase , Shoji Fukumoto , Tsuneo Oda , Hidekazu Tokuhara , Naoki Ishii , Yusuke Sasaki
IPC: C07F7/08 , C07D205/04 , C07D207/12 , C07K5/065 , C07D239/36 , C07D213/64 , C07D309/06 , C07D333/38 , C07F7/10 , C07D403/06 , C07D271/10 , C07C237/22 , C07D295/14 , C07D207/26 , C07D413/12 , C07F7/30 , C07D233/72 , C07D309/08 , C07D231/56 , C07D261/08 , C07D209/18 , C07D405/12 , C07D261/12 , C07D239/54 , C07D211/62 , C07D237/14 , C07D231/12 , C07D487/04 , A61P43/00 , A61P29/00 , A61P25/00 , A61P19/02 , A61P17/06 , A61P1/04 , C07K5/087
Abstract: The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.
-
Patent Agency Ranking
公开(公告)号：US20200010487A1
公开(公告)日：2020-01-09
申请号：US16576293
申请日：2019-09-19
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Satoshi Yamamoto , Junya Shirai , Mitsunori Kono , Yoshihide Tomata , Ayumu Sato , Atsuko Ochida , Yoshiyuki Fukase , Shoji Fukumoto , Tsuneo Oda , Hidekazu Tokuhara , Naoki Ishii , Yusuke Sasaki
IPC: C07F7/08 , C07D205/04 , C07D207/12 , C07K5/065 , C07K5/087
Abstract: The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.
-
公开(公告)号：US20180319812A1
公开(公告)日：2018-11-08
申请号：US16035277
申请日：2018-07-13
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Satoshi Yamamoto , Junya Shirai , Hiroyuki Watanabe , Shoji Fukumoto , Tsuneo Oda , Hidekazu Tokuhara , Yoshihide Tomata , Naoki Ishii , Michiko Tawada , Mitsunori Kono , Atsuko Ochida , Takashi Imada , Yoshiyuki Fukase , Tomoya Yukawa
IPC: C07D491/056 , C07F7/08 , C07D217/26 , C07D413/12 , C07D401/12 , C07D405/12 , C07D401/04 , C07D413/14 , C07D491/048 , C07D471/04 , C07D417/06 , C07D413/06 , C07D409/06 , C07D405/06 , C07D401/06 , C07D491/04
CPC classification number: C07D491/056 , C07D217/26 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/06 , C07D405/12 , C07D409/06 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D471/04 , C07D491/04 , C07D491/048 , C07F7/0812
Abstract: The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. wherein each symbol is as defined in the specification.
-
公开(公告)号：US09365520B2
公开(公告)日：2016-06-14
申请号：US14755439
申请日：2015-06-30
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Satoshi Yamamoto , Junya Shirai , Tsuneo Oda , Mitsunori Kono , Atsuko Ochida , Takashi Imada , Hidekazu Tokuhara , Yoshihide Tomata , Naoki Ishii , Michiko Tawada , Yoshiyuki Fukase , Tomoya Yukawa , Shoji Fukumoto
IPC: C07D471/04 , C07D215/00 , C07D491/14 , C07D217/26 , C07F7/08 , C07D491/048 , C07D491/056 , A61K31/4375 , A61K31/472 , A61K31/4741 , C07D217/14
CPC classification number: C07D217/26 , A61K31/4375 , A61K31/472 , A61K31/4741 , C07D217/14 , C07D471/04 , C07D491/048 , C07D491/056 , C07D491/14 , C07F7/0812
Abstract: The present invention provides a heterocyclic compound having a RORγt inhibitory action.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification. or a salt thereof.
Abstract translation: 本发明提供具有RORγt抑制作用的杂环化合物。 本发明涉及由式（I）表示的化合物：其中每个符号如说明书中所定义。 或其盐。
-
公开(公告)号：US11851449B2
公开(公告)日：2023-12-26
申请号：US17316185
申请日：2021-05-10
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Satoshi Yamamoto , Junya Shirai , Mitsunori Kono , Yoshihide Tomata , Ayumu Sato , Atsuko Ochida , Yoshiyuki Fukase , Shoji Fukumoto , Tsuneo Oda , Hidekazu Tokuhara , Naoki Ishii , Yusuke Sasaki
IPC: C07F7/08 , C07D205/04 , C07D207/12 , C07K5/065 , C07D239/36 , C07D213/64 , C07D309/06 , C07D333/38 , C07F7/10 , C07D403/06 , C07D271/10 , C07C237/22 , C07D295/14 , C07D207/26 , C07D413/12 , C07F7/30 , C07D233/72 , C07D309/08 , C07D231/56 , C07D261/08 , C07D209/18 , C07D405/12 , C07D261/12 , C07D239/54 , C07D211/62 , C07D237/14 , C07D231/12 , C07D487/04 , A61P43/00 , A61P29/00 , A61P25/00 , A61P19/02 , A61P17/06 , A61P1/04 , C07K5/087
CPC classification number: C07F7/0812 , A61P1/04 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P43/00 , C07C237/22 , C07D205/04 , C07D207/12 , C07D207/26 , C07D209/18 , C07D211/62 , C07D213/64 , C07D231/12 , C07D231/56 , C07D233/72 , C07D237/14 , C07D239/36 , C07D239/54 , C07D261/08 , C07D261/12 , C07D271/10 , C07D295/14 , C07D309/06 , C07D309/08 , C07D333/38 , C07D403/06 , C07D405/12 , C07D413/12 , C07D487/04 , C07F7/081 , C07F7/10 , C07F7/30 , C07K5/06078 , C07K5/0812
Abstract: The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.
-
公开(公告)号：US11053262B2
公开(公告)日：2021-07-06
申请号：US16576293
申请日：2019-09-19
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Satoshi Yamamoto , Junya Shirai , Mitsunori Kono , Yoshihide Tomata , Ayumu Sato , Atsuko Ochida , Yoshiyuki Fukase , Shoji Fukumoto , Tsuneo Oda , Hidekazu Tokuhara , Naoki Ishii , Yusuke Sasaki
IPC: C07F7/08 , C07D309/06 , C07D405/12 , C07D239/36 , C07D413/12 , C07D205/04 , C07C237/22 , C07D207/12 , C07D271/10 , C07F7/10 , C07F7/30 , C07K5/065 , C07D309/08 , C07D231/12 , C07D231/56 , C07D333/38 , C07D233/72 , C07D403/06 , C07D237/14 , C07D239/54 , C07D213/64 , C07D295/14 , C07D207/26 , C07D261/08 , C07D209/18 , C07D261/12 , C07D211/62 , C07D487/04 , A61P43/00 , A61P29/00 , A61P25/00 , A61P19/02 , A61P17/06 , A61P1/04 , C07K5/087
Abstract: The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.058 seconds)
